AMPLY Discovery is a biotech that uses its TALON platform—six specialized AI engines combined with two translational wet‑lab sites—to mine the non‑coding 98% of the human genome for therapeutic targets. By iteratively validating computational predictions in laboratory hubs, the company generates first‑in‑class drug candidates such as antimicrobial‑peptide aerosols and lncRNA oligonucleotides, providing pharma partners with credible go/no‑go data for novel medicines.
Funding
$1.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
3OTPFounders
Product
Problem
Drug discovery programs largely focus on the protein-coding 2% of the human genome, leaving the remaining 98% of non‑coding regions unexplored. This “dark genome” contains potential therapeutic targets that are missed by conventional approaches, limiting the pipeline of novel medicines for hard‑to‑treat diseases.
Solution
AMPLY Discovery addresses this gap with an end‑to‑end platform called TALON that combines six specialized machine‑learning engines with two world‑class translational wet‑lab sites. The AI engines analyze multi‑omic data to identify functional non‑coding elements, design candidate molecules, and prioritize experiments. Predictions are iteratively validated in the Belfast and London labs, feeding results back into the models to improve accuracy. The closed‑loop workflow enables rapid generation of first‑in‑class therapeutics such as antimicrobial‑peptide aerosols for multidrug‑resistant tuberculosis and long non‑coding RNA oligonucleotides for oncology indications. By turning computational insights into experimentally confirmed programs, AMPLY provides partners with credible go/no‑go data for advancing novel drug candidates.
Target Audience
Primary customers are pharmaceutical and biotechnology companies seeking novel, validated targets and early‑stage therapeutic candidates in areas of high unmet medical need, such as antimicrobial resistance and hard‑to‑treat cancers.
Features
- Six domain‑specific AI engines that discover targets, design molecules, and optimize experimental plans within the non‑coding genome.
- Integrated TALON discovery loop that continuously retrains models with wet‑lab validation data.
- Two translational wet‑lab hubs (Queen’s University Belfast and University of London) for high‑throughput testing of antimicrobial peptides and lncRNA oligonucleotides.
- Aerosol‑delivery platform for antimicrobial‑peptide therapies targeting respiratory infections such as MDR‑TB.
- lncRNA oligonucleotide programs aimed at difficult oncology indications including triple‑negative breast cancer and acute myeloid leukemia.
- Multi‑omic data integration (genomics, epigenomics, transcriptomics) to uncover functional elements in the dark genome.